Compare TMC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMC | ZYME |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2020 | 2022 |
| Metric | TMC | ZYME |
|---|---|---|
| Price | $3.76 | $25.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $10.90 | ★ $41.23 |
| AVG Volume (30 Days) | ★ 3.9M | 494.2K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.00 | 33.33 |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | N/A | $186.92 |
| Revenue Next Year | N/A | $16.24 |
| P/E Ratio | $20.16 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $3.40 | $16.00 |
| 52 Week High | $11.35 | $31.34 |
| Indicator | TMC | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 47.17 |
| Support Level | $3.54 | $22.10 |
| Resistance Level | $4.81 | $27.30 |
| Average True Range (ATR) | 0.20 | 1.09 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 19.35 | 33.08 |
TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.